

Subject: Artificial Intervertebral Disc Replacement (ADR) Surgery (Lumbar and Cervical)		<b>Original Effective Date:</b> 6/14/2006
Policy Number: MCP-011	<b>Revision Date(s):</b> 1/28/2009, 12/ 12/8/2015, 9/13/2018	/14/2011, 4/2/2014,
<b>Review Date:</b> 12/16/2015, 12/14/2016, 6/22/2017 MCPC Approval Date: 9/13/2018, 6/19/19, 4/23/		

# Contents

DISCLAIMER	1
DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL	1
Position Statement Criteria	3
Limitations	4
Summary of Medical Evidence	4
Coding Information	6
Resource References	6
Review/Revision History	11

## DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Policy (MCP) document and provide the directive for all Medicare members.<sup>1</sup>

## **DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL**<sup>72</sup>

Lumbar Artificial Disc



Lumbar total disc replacement (LTDR) involves replacement of a degenerating lumbar (L3-S1) intervertebral disc with an artificial, or prosthetic, disc. The artificial disc is designed to maintain the physiological range of motion and stability of the natural spine and restore disc height and vertebral alignment, and, as a result, relieve pain and prevent adjacent disc degeneration. Implantation of the artificial lumbar disc is performed under general anesthesia using the retroperitoneal or transperitoneal approach. During the surgery, the neurosurgeon may require assistance of a vascular or general surgeon in order to reduce complications that may occur during exposure and instrumentation due to the presence of vital anatomical structures such as the aorta, iliac vessels, sympathetic plexus, and intraperitoneal structures such as the bowel and ureters. An anterior retroperitoneal approach is used to expose the affected disc. The patient is placed in a supine position, and a complete discectomy is performed, including the removal of the posterior lateral recesses of the disc. The bony end plates are prepared by removing the cartilaginous end plates and any osteophytes, although the surrounding spinal ligaments are saved to maintain the stability of the implant. A trial disc and fluoroscopy may be used to determine the midline of the vertebral body for proper placement of the disc. The trial disc is subsequently removed, and the artificial disc is inserted and secured.

## Cervical Artificial Disc

Cervical artificial disc replacement has been developed as a clinical alternative to anterior cervical discectomy and fusion. The artificial disc is intended to relieve pain, restore disc height, maintain motion of the natural spine, and prevent degeneration of adjacent discs. Cervical Artificial disc implantation is typically performed by an orthopedic surgeon on an inpatient basis. The surgical procedure to implant the Prestige ST artificial disc takes 90 minutes to 2 hours to perform, and involves a cervical discectomy using a standard anterior approach. The patient is placed in a supine position and a complete discectomy is performed, including removal of the posterior lateral recesses of the disc. The bony end plates are prepared by removing the cartilaginous end plates and any osteophytes. A trial disc and fluoroscopy may be used to determine the midline of the vertebral body for proper placement of the disc. The trial disc is then removed and the artificial disc inserted and secured. Hospital stay ranges from 1 to 2 days, after which the patient can resume normal activities with minimal or no restrictions. Following artificial cervical disc replacement, use of a cervical collar is not necessary.

## FDA Information: 2 72

The FDA has approved the following artificial lumbar disc systems for surgical implantation within the spine for single-level disc replacement (activL® Artificial Disc [Aesculap Implant Systems], Charite® [DePuy Spine], and ProDisc-L [DePuySynthes]). Each device has specific labeling information but in general the devices are approved for individuals who are skeletally mature with DDD at a single level. <sup>71</sup>

The FDA has approved the following artificial cervical disc systems for single-level treatment (includes but is not limited to): The Prestige™ ST Cervical Disc and Prestige LP Cervical Disc (Medtronic Sofamor Danek, Memphis, TN), the PRODISC-C® Total Disc Replacement (Synthes, Inc., New York, NY), the BRYAN® Cervical Disc (Medtronic Sofamor Danek, Memphis, TN), Secure®-C Cervical Artificial Disc (Globus Medical, Audubon, PA) and PCM® Cervical Disc System (NuVasive, Inc., San Diego, CA). Each device has specific labeling information but in general the devices are approved for use in a skeletally mature individual for the reconstruction of a cervical disc from C3–C7 following single-level discectomy or intractable radiculopathy and/or myelopathy. The FDA has granted premarket approval to the following 2 artificial cervical



disc systems for multilevel treatment: the Prestige LP Cervical Disc System (Medtronic Inc.) and The Mobi-C Cervical Disc Prosthesis (LDR Spine USA Inc.). These devices have specific have specific labeling information but in general the devices are approved for use in skeletally mature patients for reconstruction of the disc from C3 to C7 following discectomy at 2 contiguous levels for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to abnormality localized to the level of the disc space. In 2019 the FDA approved the M6-C<sup>TM</sup> Artificial Cervical Disc that is indicated for reconstruction of the disc following single level discectomy in skeletally mature patients with intractable degenerative cervical radiculopathy with or without spinal cord compression at one level from C3 – C7.

## POSITION STATEMENT CRITERIA 1-2 3-65 72

- 1. <u>*Cervical*</u> intervertebral disc replacement may be considered medically necessary and authorized in skeletally mature individuals when all of the following criteria is met: [ALL]
  - □ Age 18-60 years old
  - Device is FDA approved for cervical disc replacement
  - Diagnosis of single level degenerative cervical disc disease with intractable radiculopathy and/or myelopathy confirmed with imaging studies
  - □ Symptoms of unremitting neck and arm pain, resulting in disability and/or neurological deficit that is refractory to all of the following:
    - Six months or more of standard medical management unless contraindicated: [ALL]
      - ◊ activity restrictions and/or;
      - $\diamond$  exercise; and
      - $\diamond$  analgesics; and
      - ♦ physical therapy
  - □ The planned implant will be used in the reconstruction of a cervical disc in one or two continuous vertebral levels between C3-C7, following single or two-level discectomy
  - □ Candidate for single or two-level anterior cervical decompression and interbody fusion
- 2. <u>*Lumbar*</u> intervertebral disc replacement may be considered medically necessary and authorized in skeletally mature individuals when all of the following criteria is met:
  - □ Age 18-60 years old
  - Device is FDA approved for lumbar disc replacement
  - Diagnosis of single level degenerative lumbar disc disease with intractable radiculopathy and/or myelopathy confirmed with imaging studies
  - □ Symptoms of unremitting back and/or leg pain, resulting in disability and/or neurological deficit that is refractory to all of the following:
    - Six months or more of standard medical management unless contraindicated: [ALL]
      - $\diamond$  activity restrictions and/or;
      - $\diamond$  exercise; and
      - $\diamond$  analgesics; and
      - $\diamond$  physical therapy



- □ The planned implant will be used in the reconstruction of a lumbar disc in only one vertebral level between L-3 to S-1, following single-level discectomy
- □ Candidate for single-level lumbar decompression and interbody fusion

#### LIMITATIONS<sup>272</sup>

- 1. Cervical Disc Replacement: each device has specific contraindications however these generally include, but are not limited to:
  - □ chronic or acute renal failure or history of renal disease
  - □ clinically significant cervical instability or significant cervical anatomical deformity or compromised vertebral bodies at the index level (e.g., ankylosing spondylitis, rheumatoid arthritis, or compromise due to current or past trauma)
  - more than one cervical level with DDD (except those specifically FDA approved for two level disease)
  - □ neck or arm pain of unknown etiology
  - □ not skeletally mature
  - □ osteopenia, osteomalacia, or osteoporosis as defined by bone mineral density T-score of -3.5, or 2.5 with vertebral crush fracture
  - □ pregnancy
  - □ prior fusion at an adjacent cervical level
  - □ prior surgery at treated level
  - □ rheumatoid arthritis or other autoimmune disease
  - □ severe facet joint pathology or involved vertebral bodies
  - □ severe insulin-dependent diabetes
  - □ spinal metastases
  - □ taking medications known to potentially interfere with bone/soft tissue healing (e.g., steroids)
- 2. Lumbar disc replacement: each device has specific contraindications however these generally include, but are not limited to:
  - **u** active systemic infection or infection localized to the site of implantation
  - □ allergy or sensitivity to implant materials
  - □ bony lumbar stenosis
  - □ isolated radicular compression syndromes, especially due to disc herniation
  - osteopenia
  - □ osteoporosis
  - □ pars defect

#### SUMMARY OF MEDICAL EVIDENCE

#### Cervical: 3-32

The published evidence consists of randomized controlled trials, clinical trials, meta-analysis, systematic reviews and prospective studies with sample sizes ranging from 50-1648 and follow-up ranging from 2-7 years.



Most RCTs compared total disc replacement (TDR) and anterior cervical discectomy and fusion (ACDF) or TDR, ACDF, and dynamic cervical implant (DCI) in adults with cervical DDD with pain that remained intractable after  $\geq 6$  weeks of conservative treatment. The most common clinical outcomes assessed were neck disability using the NDI scale, arm and neck pain using a 10-centimeter (cm) or 100-mm VAS scale, QOL using the SF-36 Health Survey (QualityMetric Inc.). Most RCTs reported overall success and significantly favored TDR over ACDF at 1 to 5 years postsurgery. Large improvements (e.g., 40 to 60 points on 100-millimeter [mm] visual analog scale [VAS]) in both arm and neck pain were observed within both TDR and ACDF groups, but between-group differences were generally very small and nonsignificant. QOL improvement was statistically significant following both TDR and ACDF. Study results showed that total disc replacement (TDR) is at least as effective as (ACDF) in improving signs and symptoms associated with degenerative disk disease (DDD) and in improving quality of life (QOL) in the short term.

## Two Level Cervical Disc Replacement 11 12 59-65

The published evidence for two level cervical disc replacement include randomized controlled trials, prospective and retrospective comparative studies, meta-analysis and systematic reviews that compared 2-level artificial cervical TDR with anterior cervical discectomy and fusion (ACDF). These studies reviewed adult patients with cervical DDD involving more than 1 disc who presented with cervical radiculopathy or myelopathy that had been unresponsive to nonsurgical treatment as candidates for 2-level TDR. The effectiveness of 2-level TDR for treatment of cervical DDD was assessed largely based on measures of neck disability, arm and/or neck pain, neurological status, HRQOL, and rates of adverse events. Overall, with regard to effectiveness, 2-level TDR appears to be at least comparable with ACDF. Overall success rates were higher with cervical TDR than with ACDF and in some studies with 5 to 7 years following treatment overall success ranged from 60.8% to 78.6% for TDR patients and 31.2% to 62.7% of ACDF patients. <sup>60 62</sup> The systematic reviews and meta-analysis concluded that multilevel TDR carries similar or superior clinical outcomes as ACDF and may be associated with lower risk for AEs and that TDR may be a safe and effective alternative to ACDF for multilevel cervical DDD. <sup>63-65</sup>

## Lumbar: 33-58

The published evidence consists of randomized controlled trials (RCTs), clinical trials, Cochrane reviews and uncontrolled studies with sample sizes ranging from 50 up to a total of 2139 and follow-up ranging from 7 to 17 years. These studies compared lumbar total disc replacement (LTDR) with fusion or conservative nonsurgical rehabilitation treatment in adults with symptomatic lumbar DDD (back pain with or without leg pain) at 1 or 2 vertebral levels (L3-S1) that did not improve with conservative treatment. Most RCTs enrolled patients 18 to 60 years of age. Most studies assessed back pain with the VAS and functional disability with the Oswestry Low Back Pain Disability Questionnaire (ODI). Results from self-reported measures of pain, functional disability, patient satisfaction, postoperative work status, and health-related quality of life (HRQoL) suggest that LTDR is comparable to spinal fusion in highly selected patients with 1-level lumbar DDD. At 24 months, most RCTs found a statistically significant and clinically relevant improvement in low back pain (defined as  $\geq$  15-point improvement in ODI scores at 24 months compared with baseline) for LTDR compared with fusion, but at 5-years follow-up, the difference between the groups was no longer significant. Study results showed that 1-level LTDR has comparable efficacy and safety relative to fusion for the treatment of symptomatic DDD in highly selected patients.



**CODING INFORMATION** THE CODES LISTED IN THIS POLICY ARE FOR REFERENCE PURPOSES ONLY. LISTING OF A SERVICE OR DEVICE CODE IN THIS POLICY DOES NOT IMPLY THAT THE SERVICE DESCRIBED BY THIS CODE IS COVERED OR NON-COVERED. COVERAGE IS DETERMINED BY THE BENEFIT DOCUMENT. THIS LIST OF CODES MAY NOT BE ALL INCLUSIVE.

СРТ	Description	
	Cervical Disc Replacement	
0095T	Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace,	
	cervical (List separately in addition to code for primary procedure)	
0098T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)	
22856	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), single interspace, cervical	
22858	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)	
22861	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical	
22864	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical	
	Lumbar Disc Replacement	
0163T	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (List separately in addition to code for primary procedure)	
0164T	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	
0165T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	
22857	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), single interspace, lumbar	
22862	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar	
22865	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar	
HCPCS	Description	
	N/A	
ICD-10	Description Diagnosis Codes: [For dates of service on or after 10/01/2015]	
G95.89	Other specified diseases of spinal cord	
G99.2	Myelopathy in diseases classified elsewhere	
M50.00	Cervical disc disorder with myelopathy, unspecified cervical region	
M50.20	Cervical disc disorder with myelopathy, mid-cervical region, unspecified level	
M50.30	Other cervical disc degeneration, unspecified cervical region	
M51.06	Intervertebral disc disorders with myelopathy, lumbar region	
M51.36	Other intervertebral disc degeneration, lumbar region	
M51.37	Other intervertebral disc degeneration, lumbosacral region	

**RESOURCE REFERENCES** 

**Government Agency** 



- Centers for Medicare & Medicaid Services (CMS) [website] Medicare Coverage Database. NCD for Lumbar Artificial Disc Replacement (LADR) #105.10. Effective 8/14/2007. Accessed at: <u>http://www.cms.gov/medicare-coverage-database/</u>
- Center for Devices and Radiological Health (CDRH). 501(k) Premarket Approval Database [search: Product code MJO]. Food and Drug Administration [website]. Accessed at: <u>http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm</u>.

## Peer Reviewed Publications

<u>Cervical</u>

- 3. Aghayev E, Bärlocher C, Sgier F, et al. Five-year results of cervical disc prostheses in the SWISS spine registry. Eur Spine J. 2013;22(8):1723-1730.
- 4. Ament JD, Yang Z, Nunley P, Stone MB, Kim KD. Cost-effectiveness of cervical total disc replacement vs fusion for the treatment of 2-level symptomatic degenerative disc disease. JAMA Surg. 2014. Epub ahead of print. October 8, 2014.
- 5. Blumenthal SL, Ohnmeiss DD et al. Reoperations in cervical total disc replacement compared with anterior cervical fusion: results compiled from multiple prospective food and drug administration investigational device exemption trials conducted at a single site. Spine (Phila Pa 1976). 2013 Jun 15;38(14):1177-82.
- 6. Burkus JK, Traynelis VC, Haid RW Jr, Mummaneni PV. Clinical and radiographic analysis of an artificial cervical disc: 7-year follow-up from the Prestige prospective randomized controlled clinical trial. J Neurosurg Spine. 2014;21(4):516-528.
- 7. Chen Y, Wang X, Lu X, Yang H, Chen D. Cervical disk arthroplasty versus ACDF for preoperative reducible kyphosis. Orthopedics. 2013;36(7):e958-e965.
- 8. Cheng L, Nie L, Li M, Huo Y, Pan X. Superiority of the Bryan disc prosthesis for cervical myelopathy: a randomized study with 3-year followup. Clin Orthop Relat Res. 2011;469(12):3408-3414.
- 9. Cheng L, Nie L, Zhang L, Hou Y. Fusion versus Bryan Cervical Disc in two-level cervical disc disease: a prospective, randomised study. Int Orthop. 2009;33(5):1347-1351.
- 10. Coric D, Kim PK et al. Prospective randomized study of cervical arthroplasty and anterior cervical discectomy and fusion with long-term follow-up: results in 74 patients from a single site. J Neurosurg Spine. 2013 Jan;18(1):36-42.
- 11. Davis RJ, Kim KD et al. Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial: clinical article. J Neurosurg Spine. 2013 Nov;19(5):532-45. doi: 10.3171/2013.6.SPINE12527. Epub 2013 Sep 6
- 12. Davis RJ, Nunley PD, Kim KD, Hisey MS, Jackson RJ, Bae HW, Hoffman GA, Gaede SE, Danielson GO 3rd, Gordon C, Stone MB. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results. J Neurosurg Spine. 2015 Jan;22(1):15-25. doi: 10.3171/2014.7.SPINE13953. PubMed PMID: 25380538.
- 13. Delamarter RB, Murrey D, Janssen ME, et al. Results at 24 months from the prospective, randomized, multicenter Investigational Device Exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients. SAS J. 2010;4:122-128.
- 14. Gao Y, Liu M et al. A meta-analysis comparing the results of cervical disc arthroplasty with anterior cervical discectomy and fusion (ACDF) for the treatment of symptomatic cervical disc disease. J Bone Joint Surg Am. 2013 Mar 20;95(6):555-61
- 15. Hisey MS, Bae HW, Davis R, et al.; Texas Back Institute Research Foundation. Prospective, randomized comparison of cervical total disc replacement versus anterior cervical fusion: results at 48 months follow-up. J Spinal Disord Tech. 2014. Epub ahead of print. October 10, 2014.



- 16. Li Z, Yu S, Zhao Y, et al. Clinical and radiologic comparison of dynamic cervical implant arthroplasty versus anterior cervical discectomy and fusion for the treatment of cervical degenerative disc disease. J Clin Neurosci. 2014;21(6):942-948.
- 17. Lu Y, McAnany SJ, Hecht AC, Cho SK, Qureshi SA. Utilization trends of cervical artificial disc replacement after FDA approval compared with anterior cervical fusion: adoption of new technology. Spine (Phila Pa 1976). 2014;39(3):249-255.
- Luo J, Gong M, Huang S, Yu T, Zou X. Incidence of adjacent segment degeneration in cervical disc arthroplasty versus anterior cervical decompression and fusion meta-analysis of prospective studies. Arch Orthop Trauma Surg. 2014a. Epub ahead of print. November 26, 2014.
- 19. Luo J, Huang S, Gong M, et al. Comparison of artificial cervical arthroplasty versus anterior cervical discectomy and fusion for one-level cervical degenerative disc disease: a meta-analysis of randomized controlled trials. Eur J Orthop Surg Traumatol. 2014b. Epub ahead of print. July 18, 2014.
- 20. McAfee PC, Reah C, Gilder K et al. A meta-analysis of comparative outcomes following cervical arthroplasty or anterior cervical fusion: results from 4 prospective multicenter randomized clinical trials and up to 1226 patients. Spine (Phila Pa 1976). 2012 May 15;37(11):943-52.
- 21. Mermen C, Scheme P, Rochelle F, et al. Heterotypic ossification in total cervical artificial disc replacement. Spine 2006; 31(24):2802-2806.
- 22. Mummaneni PV, Amin BY et al. Cervical artificial disc replacement versus fusion in the cervical spine: a systematic review comparing long-term follow-up results from two FDA trials. Evid Based Spine Care J. 2012 Feb;3(S1):59-66. Accessed at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519406/
- 23. Mummaneni PV, et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. J Neurosurg Spine. 2007 Mar;6(3):198-209.
- 24. Murrey D, Janssen M, Delamarter R, et al. Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the Prodisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. Spine J. 2009 Apr;9(4):275-86
- 25. Nabhan A. Segmental kinematics and adjacent level degeneration following disc replacement versus fusion: RCT with three years of follow-up. Long term Eff Medical Implants. 2007;17(3):229-36
- 26. Phillips FM, Lee JY, Geisler FH, et al. A prospective, randomized, controlled clinical investigation comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. 2-year results from the US FDA IDE clinical trial. Spine (Phila Pa 1976). 2013;38(15):E907-E918.
- 27. Vaccaro A, Beutler W, Peppelman W, et al. Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two-year results from a prospective, randomized, controlled, multicenter investigational device exemption study. Spine (Phila Pa 1976). 2013;38(26):2227-2239.
- 28. Yin S, Yu X, Zhou S, Yin Z, Qiu Y. Is cervical disc arthroplasty superior to fusion for treatment of symptomatic cervical disc disease? A meta-analysis. Clin Orthop Relat Res. 2013;471(6):1904-1919.
- 29. Yu L, Song Y, Yang X, Lv C. Systematic review and meta-analysis of randomized controlled trials: comparison of total disk replacement with anterior cervical decompression and fusion. Orthopedics. 2011 Oct 5;34(10):e651-8.
- Zhang HX, Shao YD, Chen Y, et al. A prospective, randomised, controlled multicentre study comparing cervical disc replacement with anterior cervical decompression and fusion. Int Orthop. 2014;38(12):2533-2541.
- 31. Zhao H, Cheng L, Hou Y, et al. Multi-level cervical disc arthroplasty (CDA) versus single-level CDA for the treatment of cervical disc diseases: a meta-analysis. Eur Spine J. 2014. Epub ahead of print. June 25, 2014.
- 32. Zigler JE, Delamarter R, Murrey D, Spivak J, Janssen M. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease: five-year results of a Food and Drug Administration study. Spine (Phila Pa 1976). 2013;38(3):203-209.



<u>Lumbar</u>

- 33. Berg S, Tropp HT, Leivseth G. Disc height and motion patterns in lumbar spine in patients operated with total disc replacement or fusion for discogenic back pain. Results from a randomized controlled trial. Spine J. 2011;11(11):991-998.
- 34. Berg S, Tullberg T, Branth B, Olerud C, Tropp H. Total disc replacement compared to lumbar fusion: a randomized controlled trial with 2-year follow-up. Eur Spine J. 2009;18(10):1512-1519.
- 35. David T. Long-term results of one-level lumbar arthroplasty: minimum 10-year follow-up of the CHARITE artificial disc in 106 patients. Spine. 2007;32(6):661-666.
- 36. Delamarter R, Zigler JE, Balderston RA, Cammisa FP, Goldstein JA, Spivak JM. Prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement compared with circumferential arthrodesis for the treatment of two-level lumbar degenerative disc disease: results at twenty-four months. J Bone Joint Surg Am. 2011;93(8):705-715.
- 37. Geisler FH, Guyer RD, Blumenthal SL, et al. Effect of previous surgery on clinical outcome following 1level lumbar arthroplasty. J Neurosurg Spine. 2008;8(2):108-114.
- 38. Geisler FH, McAfee PC, Banco RJ, et al., Prospective, randomized, multicenter FDA IDE study of CHARITÉ artificial disc versus lumbar fusion: effect at 5-year follow-up of prior surgery and prior discectomy on clinical outcomes following lumbar arthroplasty. SAS J. 2009; 3(1):17-25.
- 39. Gornet MF, Burkus JK, Dryer RF, Peloza JH. Lumbar disc arthroplasty with Maverick disc versus standalone interbody fusion: a prospective, randomized, controlled, multicenter investigational device exemption trial. Spine (Phila Pa 1976). 2011;36(25):E1600-E1611.
- 40. Guyer RD, McAfee PC, Banco RJ et al. Prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of lumbar total disc replacement with the Charite artificial disc versus lumbar fusion: Five-year follow-up. The Spine Journal 2008a Sep [Epub ahead of print
- 41. Guyer RD, Pettine K, Roh JS, et al. Comparison of 2 lumbar total disc replacements: results of a prospective, randomized, controlled, multicenter Food and Drug Administration trial with 24-month follow-up. Spine (Phila Pa). 2014;39(12):925-931
- 42. Hellum C, Johnsen LG, Gjertsen Ø, et al. Predictors of outcome after surgery with disc prosthesis and rehabilitation in patients with chronic low back pain and degenerative disc: 2-year follow-up. Eur Spine J. 2012a;21(4):681-690.
- 43. Hellum C, Johnsen LG, Storheim K, et al. Surgery with disc prosthesis versus rehabilitation in patients with low back pain and degenerative disc: two year follow-up of randomised study. BMJ. 2011;342:d2786.
- Jacobs W, Van der Gaag NA, Tuschel A, de Kleuver M, Peul W, Verbout AJ, Oner FC. Total disc replacement for chronic back pain in the presence of disc degeneration. <u>*Cochrane Database Syst Rev.*</u> 2012 Sep 12;9:CD008326. doi: 10.1002/14651858.CD008326.pub2.
- 45. Johnsen LG, Brinckmann P, Hellum C, Rossvoll I, Leivseth G. Segmental mobility, disc height and patient-reported outcomes after surgery for degenerative disc disease: a prospective randomized trial comparing disc replacement and multidisciplinary rehabilitation. Bone Joint J. 2013;95-B(1):81-89.
- 46. Kafer W, Clessienne CB, Daxle M et al. Posterior component impingement after lumbar total disc replacement: a radiographic analysis of 66 Prodisc L prosthesis in 56 patients. Spine (Phila Pa 1976). 2008 Oct 15;33(22):2444-9
- 47. Lemaire JP, Carrier H, Ali el-HS, Skalli W, Lavaste F. Clinical and radiological outcomes with the CHARITE artificial disc: a 10 year minimum follow-up. Journal Spinal Disorders Technology 2005. Aug;18(4):353-9.
- 48. McAfee PC, Cunningham B, Holsapple G, et al. A prospective, randomized, mulitcenter Food and Drug Administration investigational device exemption study of lumbar total disc replacement with the CHARITE artificial disc versus lumbar fusion: part II: evaluation of radiographic outcomes and



correlation of surgical technique accuracy with clinical outcomes. Spine (Phila Pa 1976). 2005;30(14):1576-1583.

- 49. McAfee PC, Geisler FH, Saiedy SS et al. Revisability of the CHARITE artificial disc replacement: analysis of 688 patients enrolled in the U.S. IDE study of the CHARITE artificial disc. Spine. 2006;31(11):1217-1226.
- 50. Oktenoglu T, Ozer AF, Sasani M, Ataker Y, Gomleksiz C, Celebi I. Posterior transpedicular dynamic stabilization versus total disc replacement in the treatment of lumbar painful degenerative disc disease: a comparison of clinical results. Adv Orthop. 2013;2013:874090.
- 51. Punt I, Visser VM, Van Rhijn L, Kurtz S et al. Complications and reoperations of the SB Charite lumbar disc prosthesis: experience in 75 patients. European Spine Journal 2008 17:36-43.
- 52. Putzier M, et al. Charité total disc replacement--clinical and radiographical results after an average followup of 17 years. Eur Spine J. 2006 Feb;15(2):183-95.
- 53. Siepe CJ, Heider F, Wiechert K, Hitzl W, Ishak B, Mayer MH. Mid- to long-term results of total lumbar disc replacement: a prospective analysis with 5- to 10-year follow-up. Spine J. 2014;14(8):1417-1431
- 54. Tropiano P, Huang RC, Girardi FP, Cammisa FP Jr, Marnay T. Lumbar total disc replacement. Seven to eleven year follow-up. Journal of Bone Joint Surgery America 2005 Mar;87(3):490-6.
- 55. Wei J, Song Y et al. Comparison of artificial total disc replacement versus fusion for lumbar degenerative disc disease: a meta-analysis of randomized controlled trials. Int Orthop. 2013 Jul;37(7):1315-25.
- 56. Yajun W, Yue Z et al. A meta-analysis of artificial total disc replacement versus fusion for lumbar degenerative disc disease. Eur Spine J. 2010 Aug;19(8):1250-61.
- 57. Zigler J, Delamarter R, Spivak JM, et al. Results of the prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the Prodisc-L total disc replacement versus circumferential fusion for the treatment of 1-level degenerative disc disease. Spine. 2007;32(11):1155-1163.
- 58. Zigler JE, Delamarter RB. Five-year results of the prospective, randomized, multicenter, Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement versus circumferential arthrodesis for the treatment of single-level degenerative disc disease. J Neurosurg Spine. 2012 Dec;17(6):493-501.

## Two Level Cervical

- 59. Jackson RJ, Davis RJ, Hoffman GA, et al. Subsequent surgery rates after cervical total disc replacement using a Mobi-C cervical disc prosthesis versus anterior cervical discectomy and fusion: a prospective randomized clinical trial with 5-year follow-up. J Neurosurg Spine. 2016;24(5):734-745.
- 60. Radcliff K, Coric D, Albert T. Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial. J Neurosurg Spine. 2016;25(2):213-224.
- 61. Gornet MF, Lanman TH, Burkus JK, et al. Cervical disc arthroplasty with the PRESTIGE LP disc versus anterior cervical discectomy and fusion, at 2 levels: results of a prospective, multicenter randomized controlled clinical trial at 24 months. J Neurosurg Spine. 2017;26(6):653-667.
- 62. Lanman TH, Burkus JK, Dryer RG, Gornet MF, McConnell J, Hodges SD. Long-term clinical and radiographic outcomes of the Prestige LP artificial cervical disc replacement at 2 levels: results from a prospective randomized controlled clinical trial. J Neurosurg Spine. 2017;27(1):7-19.
- 63. Kuang L, Chen Y, Wang B, Li L, Lu G. Cervical disk arthroplasty versus anterior cervical decompression and fusion for the treatment of 2-level cervical spondylopathy: a systematic review and meta-analysis. Clin Spine Surg. 2016;29(9):372-382.
- 64. Joaquim AF, Riew KD. Multilevel cervical arthroplasty: current evidence. A systematic review. Neurosurg Focus. 2017;42(2):E4.



65. Wu TK, Wang BY, Meng Y, et al. Multilevel cervical disc replacement versus multilevel anterior discectomy and fusion: a meta-analysis. Medicine (Baltimore). 2017;96(16):e6503.

## **Professional Society Guidelines**

- 66. National Institute for Health and Clinical Excellence (NICE) [website]. Accessed at: https://www.nice.org.uk/
  - Prosthetic intervertebral disc replacement in the cervical spine. IPG 341. May, 2010.
  - Prosthetic intervertebral disc replacement. IPG306. July 2009. Updated June 12, 2012.
- 67. North American Spine Society (NASS). Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care. Diagnosis and Treatment of Cervical Radiculopathy from Degenerative Disorders. 2010. Available at: <u>https://www.spine.org/Documents/ResearchClinicalCare/Guidelines/CervicalRadiculopathy.pdf</u>.
- 68. Ontario Health Technology Assessment. Cervical Artificial Disc Replacement Versus Fusion for Cervical Degenerative Disc Disease. Feb, 2019. Accessed at: <u>https://www.hqontario.ca/Evidence-to-Improve-Care/Health-Technology-Assessment/Reviews-And-Recommendations/Cervical-Artificial-Disc-Replacement-Versus-Fusion-for-Cervical-Degenerative-Disc-Disease</u>

#### **Other Resources**

- 69. Advanced Medical Review (AMR): Policy reviewed by a practicing physician Board certified in Orthopaedic Surgery, Surgery Spine. Feb 2, 2014 & August 26, 2018.
- Blue Cross Blue Shield Association (BC/BS). Artificial Lumbar Disc Arthroplasty. Technology Evaluation Center (TEC). January 2014. Volume 28, No. 7. Chicago, IL: Blue Cross and Blue Shield Association.
- 71. California Technology Assessment Forum.
  - Artificial disc replacement for degenerative disc disease of the lumbar spine. February, 2007.
  - Artificial disc replacement for degenerative disc disease of the cervical spine. Oct, 2009.
- 72. Hayes a TractManager Company. Winifred Hayes Inc. Lansdale, PA.
  - Artificial disc replacement for cervical degenerative disc disease. Dec, 2014. Updated Dec, 2015.
  - Lumbar total disc replacement for degenerative disc disease. August, 2015. Updated July, 2018.
  - Comparative effectiveness review: Single-Level Artificial Disc Replacement for Cervical Degenerative Disc Disease. Aug, 2018. Updated Nov, 2020.
  - Comparative effectiveness review: Multilevel Artificial Disc Replacement for Cervical Degenerative Disc Disease. October, 2018. Updated Jan, 2020.
  - Comparative Effectiveness Review of Lumbar Total Disc Replacement for Degenerative Disc Disease. April, 2019. Updated Aug, 2020.
  - M6-C Artificial Cervical Disc (Spinal Kinetics LLC). June, 2019. [archived July 2020]
  - M6-C Artificial Cervical Disc (Orthofix) for the Treatment of Cervical Degenerative Disc Disease. Oct, 2020.
- 73. UpToDate: [website]: Waltham, MA: Walters Kluwer Health; 2021.
  - Chou R, Atlas S, Sokol H. Subacute and chronic low back pain: surgical treatment.
  - Robinson J, Kothari M. Treatment of cervical radiculopathy.

## **REVIEW/REVISION HISTORY**

06/14/06: Policy created



01/28/09: Policy had minor revisions, no changes to criteria and procedure remains investigational.

12/14/11: Policy reviewed, no new evidence found, procedure remains investigational.

04/2/14: This policy was reviewed and based on new evidence it was revised to include new coverage criteria for the cervical artificial disc in patients who meet very specific criteria. The lumbar disc replacement remains unproven due to insufficient evidence.

12/16/2015: The policy was reviewed and updated to include criteria for lumbar artificial disc replacement based on new evidence.

12/14/16, 6/22/17: Policy reviewed, no changes

9/13/18: Policy reviewed, changes include new criteria for 2 level cervical disc replacement based on new evidence, and updated the following sections: FDA information and contraindications; references and coding tables.

6/19/19: Policy reviewed, no changes to the criteria. Updated coding. The FDA approved one new device called the M6-C<sup>™</sup> Artificial Cervical Disc.

4/23/20: Policy reviewed, no changes to criteria. One code deleted [0375T].

2/8/21: Policy reviewed, no changes to criteria. One new guideline found and added as reference #68. Added codes: 0095T and 0098T.